Three Stocks Nobody's Talking About That Deserve Your Attention Right Now
Figma's IPO crater, a spun-off ice cream empire, and a crypto exchange with a 36% single-day pop — the crowd is looking the wrong way
Ticker Ratings
| Ticker | Rating | Entry Price | Current | $ Gain | % Gain |
|---|---|---|---|---|---|
| FIG Figma, Inc. | buy | $23.13 | — | — | — |
Everyone's busy refreshing their $NVDA positions. Meanwhile, a few interesting names are doing interesting things in the background — the kind of stuff that gets missed when a Beijing summit is eating all the oxygen in the room.
$FIG (Figma) is the most compelling setup here. Bloomberg's Stock Movers segment highlighted a 9% pre-market surge after Q4 revenue beat estimates with 54% growth in AI-powered consumption metrics. The stock got absolutely obliterated post-IPO — down nearly 80% from its $122 highs — which means the bar is low, the expectations are buried, and any acceleration looks like a miracle. Figma argues, credibly, that design requires specialized human skills that general AI can't easily replace. That's a moat people keep underestimating.
$MNKTD isn't the play here — but Magnum Ice Cream (spun out of Unilever, ticker $MAGN on NYSE) is a different story. Shares jumped 22% to their highest since its December listing on 5x average volume, with Reuters reporting Blackstone and other PE firms circling a potential takeover of the $10.7B brand portfolio — Ben & Jerry's, Cornetto, Breyers, Klondike. PE firms apparently waiting on summer sales data before pulling the trigger. Classic 'wait for the data, miss the move' setup.
Finally, $GMIN (Gemini Space Station) — the Winklevoss twins' crypto exchange — popped 36% in a single session after the brothers injected a $100M strategic investment at $14/share, even though the stock trades around $5.25 and is down 47% year-to-date. Yes, they laid off 30% of staff. Yes, crypto headwinds are real. But founders buying in at nearly 3x the market price with $100M of their own money is a signal worth watching — even if it smells a little like a lifeline.
Three completely different stories, three completely different risk profiles — but none of them are on anyone's radar right now, which is exactly the point.